Clinical Trial Update: Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study [Phase 2]

View source ↗

Summary

A Phase II single-arm study evaluating vorolanib as third-line or later monotherapy for advanced non-small cell lung cancer; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vorolanib (vorolanib)

Snippet

Sponsor: Li-kun Chen | Conditions: Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer | Phase 2 | Status: RECRUITING